La cadena de opciones muestra datos clave de las opciones de acciones de Xeris Biopharma Holdings a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Xeris Biopharma Holdings..

Xeris Biopharma Holdings (NASDAQ:XERS) Bolsa, Cadena de Opciones

Xeris Biopharma Holdings

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Xeris Biopharma Holdings, Inc. - Common Stock

Xeris Biopharma Holdings Inc

Fintech giant PayPal Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) said Tuesday it was committed to boosting cryptocurrency adoption, with a particular emphasis on its PayPal USD (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PYUSD</a>) stablecoin.
What Happened:&nbsp;During the company&#8217;s first-quarter&nbsp;earnings call, CEO Alex Chriss said PayPal was &#8220;making strides&#8221; and &#8220;moving quickly&#8221; to bring the benefits of cryptocurrency and stablecoins to its user base.
&#8220;Last week, we introduced the ability to earn rewards for holding PYUSD. This will increase the adoption and use of digital currencies for everyday commerce, from sending money internationally to making purchases and more,&#8221; Chriss stated.
Regarding PYUSD, the top executive said PayPal has been strengthening its ties with cryptocurrency industry giants such as Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) to facilitate easier access and usage.
Moreover, the company&#8217;s strategic move to add PYUSD to the Solana blockchain is seen as an attempt to expand its crypto-related services. This move is in line with the rising dominance of stablecoins in the global financial system, as highlighted by tech investor Chamath Palihapitiya. He noted that the weekly transaction volumes of stablecoins have surpassed that of Visa Inc.
See Also: <a href="https://www.benzinga.com/25/04/44621245/gold-backed-cryptos-match-yellow-metals-highs-following-trumps-liberation-day-shock"></a><a href="https://www.benzinga.com/25/04/44971891/sec-teams-up-with-nayib-bukele-led-el-salvador-for-a-crypto-regulatory-sandbox">SEC Zooms In On Nayib Bukele-Led El Salvador&#8217;s Crypto Regulation Model</a>
Why It Matters: PayPal has strategically invested in digital assets, particularly stablecoins, to capitalize on their growing importance in the global financial system.
Last year, it launched <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/39068774/paypal-launches-pyusd-stablecoin-on-solana">PYUSD</a>, a dollar-backed cryptocurrency, on the Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) blockchain. As of this writing, the stablecoin had a market capitalization of $880 million, making it the sixth-largest overall.
Additionally, PayPal allows customers to buy and sell cryptocurrencies such as Bitcoin (BTC) and Ethereum (ETH), as well as use them for online purchases.
The company <a href="https://www.benzinga.com/news/earnings/25/04/45067312/paypal-earnings-beat-but-slower-spending-and-checkout-use-weigh-on-results">reported its first-quarter financials</a> on Tuesday, beating earnings predictions but falling short of revenue expectations.
Price Action: Shares of PayPal dipped 0.24% in after-hours trading after closing up 2.14% at $66.32 during Tuesday's regular trading session, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. Year-to-date, the stock has lost over 22% of its value.
PayPal recorded a moderate reading on some of its key indicators, including momentum, growth, and quality. Check out the <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Benzinga Edge Stock Rankings</a> to see how rival fintech firms stack up.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="498" height="186" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30015747/Screenshot-2025-04-30-112732.png" alt="" class="wp-image-894103" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30015747/Screenshot-2025-04-30-112732.png 498w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30015747/Screenshot-2025-04-30-112732-300x112.png 300w" sizes="(max-width: 498px) 100vw, 498px" /></figure>
Photo Courtesy: Michael Vi on Shutterstock.com
Read Next: 
<ul>
<li><a href="https://benzinga.com/news/legal/25/04/45077156/trump-affiliated-world-liberty-financial-defies-ethics-concerns-raises-550-million" target="_blank" rel="noreferrer noopener">Trump-Affiliated World Liberty Financial Defies Ethics Concerns, Raises $550 Million</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

News

$PYUSD

$SOL

COIN

PYPL

PayPal CEO Says 'Moving Quickly' To Bring Crypto, Stablecoin Benefits To Users — Fintech Giant Partners With Coinbase To Boost Solana-based PYUSD

CORRECTION: Piper Sandler analyst Derek Podhaizer maintains Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) with a Neutral and lowers the price target from $46 to $44.

Price Target

Analyst Ratings

CORRECTION: Piper Sandler Maintains Neutral on Schlumberger, Lowers Price Target to $44

<ul>
<li>SEC Comment Letter Cleared</li>
<li>Publication Delay of Annual Financial Report to on or around 9 May 2025
<ul>
<li>2024 Preliminary Unaudited Financial Highlights</li>
</ul>
</li>
</ul>

ARBK

Argo Blockchain Postpones 2024 Financials, Requests Trading Suspension Amid Audit Completion; Provides Preliminary 2024 Revenue $47M Down From $50.6M YoY, Loss Widens To $54.4M From $34.6M YoY

Capital Markets Days Following the <a href="https://www.globenewswire.com/Tracker?data=0GD_YlLwZJdkTn_SnNiXtsEsNfdfv-lAyn7SauZZGxzbh9vKqmhJAZ7o3Ln7Ro8Y5MBbTL6fa4b1QaZesrR2qm4zNgLxOBnN8p26ggC9N8FkbW9raYbIDCvfTqLti80Sp50HaixkkpI9rEZoSlw7PVwqfNCn6yHullhpRlbUQjI=">announcement on 22 April</a> of the signed term sheet for a stock-for-stock merger with Golden Ocean, with &nbsp;CMB.TECH as surviving entity, both companies have hosted Capital Markets Days in Antwerp, Belgium on 24 April 2025 and in Oslo, Norway on 29 April 2025 together. The presentations, recordings and transcripts of these Capital Markets Days are available on the <a href="https://www.globenewswire.com/Tracker?data=KqcPdpNcHe249MUpMK85AhBz5OedPubJ7-J2vUpiKsLKqy8A0wxX1vJaqk_-bj3OBWRhtAIRUUO6T75BuqMNvmsaEQDoYLmRyPMToctty0H8YMD_zWRtPpdxP3J_GjNK4lz2pWt9Jg3LyzAKDR2V_LAd3zjuRwu_SMbDWHmAtsw=">CMB.TECH website.</a>

CMBT

CMB.TECH Announces VLCC Sales, Merger Milestones, And New Earnings Calendar Amid Golden Ocean Integration

SDZNY

Sandoz Q1 Revenue Rises 3% To $2.48B, Boosted By Volume Growth Despite Pricing Pressure; For 2025, Expects Mid-Single-Digit Sales Growth And ~21% Core EBITDA Margin

The Future Fund Managing Partner, Gary Black, cautioned investors on Tuesday against Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) robotaxi valuations that project share prices of $2,000 or higher, arguing that such forecasts ignore market realities and competition.
What Happened: Black criticized supply-based approaches that assume Tesla will capture nearly all ride-hailing business from Uber Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) and Lyft Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>), noting that even if Tesla captured the entire profits of Uber and Lyft combined, the impact on its earnings would be minimal—adding $1.50 per share to Tesla's Earnings Per Share.
&#8220;Tesla doesn&#8217;t have a first-mover advantage, has no ride-hailing marketing, and hasn&#8217;t been approved for a single autonomous deployment license in any state yet,&#8221; Black wrote on X, adding that both Uber and Lyft will likely offer fully autonomous rides concurrently with Tesla.
Black&#8217;s skepticism extends to Tesla&#8217;s <a href="https://www.benzinga.com/markets/25/04/44979720/teslas-robotaxi-launch-in-june-will-likely-be-a-non-event-says-gary-black-this-isnt-really-a-test-market-its-an-experiment">upcoming Austin robotaxi launch</a>, which he recently described as an &#8220;experiment&#8221; rather than a true market test, with only 10-20 vehicles initially deployed.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I keep seeing <a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a> price targets that incorporate Robotaxi valuations of $2,000/share, $3,000/share or more. Most erroneously assume TSLA somehow takes 99% of the ride-hailing business away from UBER and LYFT once TSLA is approved for unsupervised autonomy and is awarded…
&mdash; Gary Black (@garyblack00) <a href="https://twitter.com/garyblack00/status/1917345526837830080?ref_src=twsrc%5Etfw">April 29, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/04/45090925/trumps-call-to-jeff-bezos-over-amazons-tariff-display-plans-draws-criticism-from-peter-schiff-this-is-the-type-of-stuff-you-might-expect-to-see-in-china">Trump&#8217;s Call To Jeff Bezos Over Amazon&#8217;s Tariff Display Earns Peter Schiff&#8217;s Ire: &#8216;Type Of Stuff You Might Expect To See In China&#8217;</a>
Why It Matters: Black&#8217;s concerns contrast sharply with ARK Invest CEO Cathie Wood&#8216;s bullish $2,600 price target, which values <a href="https://www.benzinga.com/news/25/03/44345980/cathie-wood-stands-by-teslas-2600-price-target-despite-40-stock-drop-its-winner-take-most">Tesla at over $9 trillion by 2029</a>. Wood views robotaxis as an &#8220;$8 trillion to $10 trillion opportunity&#8221; that could transform Tesla from a manufacturer to a software company with margins approaching 90%.
Despite recent positive movement after Tesla&#8217;s quarterly earnings call, where CEO Elon Musk announced he would &#8220;significantly&#8221; reduce his time at the Department of Government Efficiency, Black maintains that regulatory realities will prevent Tesla from dominating the <a href="https://www.benzinga.com/25/04/44945402/wedbushs-dan-ives-raises-teslas-price-target-to-350-as-musk-promises-to-significantly-reduce-doge-time">autonomous ride-hailing market.</a>
&#8220;Despite Tesla&#8217;s fleet, data, and compute advantages,&#8221; Black wrote, &#8220;regulators will ensure that others are approved soon after. And Tesla&#8217;s lack of marketing skills remains its Achilles heel.&#8221;
Benzinga Edge&#8217;s Stock Rankings indicate that while Tesla faces a short- to long-term negative price trend, it still outperforms Lucid Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>), Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>), and Nio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) in terms of momentum. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Sign up for more insights</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/04/45089307/trump-says-hes-already-ended-inflation-at-michigan-rally-held-to-mark-100-days-in-office-promises-to-protect-medicare-and-social-security-democrats-plan-senate-ba" target="_blank" rel="noreferrer noopener">Trump Says He's ‘Already Ended Inflation' At Michigan Rally Held To Mark 100 Days In Office, Promises To Protect Medicare And Social Security — Democrats Plan Senate Barrage</a></li>
</ul>
Photo Courtesy: Ian Dewar Photography On Shutterstock.com
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Markets

LCID

LYFT

RIVN

TSLA

UBER

Tesla's 'Marketing Skills Remain Its Achilles Heel,' Says Gary Black As Robotaxi Valuations Ignore Market Limits—Full Uber, Lyft Profits Still Fall Short Of $2,000 Target

Economist Justin Wolfers pushed back against President Donald Trump&#8217;s inconsistent recent remarks on trade deals, taxes, and tariff revenue, calling his position "fundamentally incoherent."
What Happened: On Tuesday, the Australian economist dismissed Trump's claim that tariff revenue could be used to reduce or eliminate income taxes. Speaking on Yahoo Finance's The Morning Brief, Wolfers was blunt: &#8220;The president is lying, it's that simple,&#8221; he said, adding that there is &#8220;no bill, process, or proposal to Congress&#8221; backing such a plan.
What&#8217;s more concerning than the claim itself is the "fundamental incoherence" of Trump's position, arguing that tariff revenue could replace income taxes, while simultaneously pushing for trade deals that would reduce those very tariffs, Wolfers says.
See More: <a href="https://www.benzinga.com/media/25/04/45089307/trump-says-hes-already-ended-inflation-at-michigan-rally-held-to-mark-100-days-in-office-promises-to-protect-medicare-and-social-security-democrats-plan-senate-ba">Trump Says He&#8217;s &#8216;Already Ended Inflation&#8217; At Michigan Rally Held To Mark 100 Days In Office, Promises To Protect Medicare And Social Security — Democrats Plan Senate Barrage</a>
&#8220;The president's got a choice,&#8221; Wolfers says. He can either strike trade deals that open global markets to American businesses and give U.S. consumers access to international goods, or &#8220;stick with very high tariffs and get some revenue out of it — you cannot have both.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The President has a choice: Deals, or tariff revenue. You can have one, but you can&#39;t have both. <a href="https://t.co/eZuMBurvmt">pic.twitter.com/eZuMBurvmt</a>
&mdash; Justin Wolfers (@JustinWolfers) <a href="https://twitter.com/JustinWolfers/status/1917195865602593178?ref_src=twsrc%5Etfw">April 29, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
&#8220;That's the whole problem with this tariff policy, what the president wants has changed day to day,&#8221; Wolfers says. He noted that the rationale behind it all has shifted repeatedly, from national security and reshoring manufacturing to raising revenue and cutting the trade deficit.
This uncertainty, Wolfers says, is making it difficult for businesses to plan ahead, much like America's foreign trade partners, who need clarity on whether and how to engage in negotiations with the U.S.
Why It Matters: Wolfers has been a <a href="https://benzinga.com/markets/equities/25/04/44620423/trumps-sweeping-tariffs-could-cost-us-20-trillion-crash-markets-warn-economists-monstrously-destructive">vocal critic of Trump&#8217;s tariffs</a> and chaotic economic policies since the very beginning, posting just a day after &#8220;Liberation Day&#8221; that the tariffs would be &#8220;monstrously destructive,&#8221; and would ultimately hurt &#8220;working Americans more than anyone else.&#8221;
Several other leading experts have been <a href="https://benzinga.com/markets/25/04/44944580/trump-says-tariffs-could-replace-income-tax-experts-warn-the-math-doesnt-work">skeptical of Trump&#8217;s proposal</a> to replace income tax with tariffs over the past week. Mark Zandi, the chief economist at Moody&#8217;s stated that the IRS has already collected $1.14 trillion in income taxes this year, and that &#8220;If you get to $100 billion to $200 billion [in tariff revenue], you&#8217;ll be pretty lucky.&#8221;
The administration's &#8220;shock and awe&#8221; tariff strategy has <a href="https://www.benzinga.com/25/04/44680956/billionaire-banker-backs-trumps-shock-and-awe-tariff-policies-slams-bill-ackmans-call-for-90-day-pause">drawn some support</a>, including from Andrew Beal, founder of Beal Financial Corporation, who argued that the tariffs are necessary to promote fair trade and redefine America's role in the global economy.
Photo Courtesy: Evan El-Amin On Shutterstock.com
Read More: <a href="https://www.benzinga.com/markets/equities/25/04/45090925/trumps-call-to-jeff-bezos-over-amazons-tariff-display-plans-draws-criticism-from-peter-schiff-this-is-the-type-of-stuff-you-might-expect-to-see-in-china">Trump&#8217;s Call To Jeff Bezos Over Amazon&#8217;s Tariff Display Earns Peter Schiff&#8217;s Ire: &#8216;Type Of Stuff You Might Expect To See In China&#8217;</a>

Government

Trump Can Either Have His Cake Or Eat It, Economist Justin Wolfers Calls Out President's 'Fundamental Incoherence' On Trade Deals And Tariffs

• Net revenues of €35.8 billion, down 14% compared to Q1 2024 primarily due to lower shipment volumes, as well as unfavorable mix and pricing&nbsp;
• Consolidated shipments(1) of 1,217 thousand units, down 9%, reflect lower North American production, a consequence of extended holiday downtime in January, product transition impacts and lower industry LCV volumes in Enlarged Europe • The Company is suspending its 2025 financial guidance due to tariff-related uncertainties&nbsp;
• The Company is highly engaged with policymakers on tariff policies, while taking action to reduce impacts

STLA

Stellantis Q1 Revenue Falls 14% to €35.8B; Shipments Down 9% to 1.22M Units on North America Downtime And EU LCV Weakness; Suspends 2025 Guidance Due To Tariff-Related Uncertainties

Macro Economic Events

Econ #s

Economics

Germany Retail Sales (MoM) For March -0.2% Vs. -0.4% Est.; 0.2% (Revised) Prior

U.K. Nationwide HPI (MoM) For April -0.6% Vs. -0.1% Est.; 0.0% Prior

U.K. Nationwide HPI (YoY) For April 3.4% Vs. 4.1% Est.; 3.9% Prior

HEC Montréal's ERPsim Lab Secures $2M For AI-Powered Data Visualization Project With SAP Canada And Partner Universities

<ul>
<li>Early market traction underscores strong market demand and momentum, confirms long-term strategy ahead of the first official FX product launch this June, securing recognition from an East Coast business validates FF's unique "Three Pillars" model of user acquisition, co-creation, and user operations.</li>
</ul>

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

Faraday Future's "Three Pillars" Strategy Pays Off With First FX Super One Deal, Reinforcing Global EV Ambitions

ADXN

Addex Expands Dipraglurant Strategy With Exclusive IP Access From Sinntaxis Targeting Brain Injury Functional Recovery

France Gross Domestic Product (QoQ) Preliminary For Q1 0.1% Vs. 0.1% Est.; -0.1% Prior

France Gross Domestic Product (YoY) Preliminary For Q1 0.8% Vs. 0.7% Est.; 0.8% (Revised) Prior

France Consumer Spending (MoM) For March -1.0% Vs. 0.0% Est.; -0.2% (Revised) Prior

Reported Earlier, China Caixin Manufacturing Purchasing Managers Index For April 50.4 Vs. 49.7 Est.; 51.2 Prior

Reported Earlier, China Non-Manufacturing Purchasing Managers Index For April 50.4 Vs. 50.6 Est.; 50.8 Prior

Reported Earlier, China Manufacturing Purchasing Managers Index For April 49.0 Vs. 49.7 Est.; 50.5 Prior

Press Releases

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Expects to Exceed Full-Year 2024 Financial Guidance

The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness

Xeris to Participate in Upcoming Investor Conferences

Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025

Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid

Comments

Xeris Biopharma Holdings

Xeris Biopharma Holdings (XERS) Opciones

Xeris Biopharma Holdings (NASDAQ:XERS) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL